Merck: four new approvals for Keytruda in Japan

(CercleFinance.com) - Another pharma big in Japan today.
.. Merck announces that its blockbuster Keytruda has been approved by Japanese health authorities for four new indications.

Merck's anti-PD-1 therapy, Keytruda, is now approved when combined with chemotherapy as neoadjuvant therapy and continued as monotherapy after surgery in patients with certain breast cancers (high-risk, hormone receptor-negative and human epidermal growth factor 2 (HER2)-negative cancers).

Keytruda has also been approved in Japan as a single agent for the adjuvant treatment of certain patients with renal cell carcinoma (RCC) at increased risk of recurrence after nephrectomy, or after nephrectomy and resection of metastatic lesions.

Finally, Keytruda has also been approved in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with advanced or recurrent cervical cancer who have not received prior chemotherapy and are not eligible for curative treatment.


Copyright (c) 2022 CercleFinance.com. All rights reserved.